Literature DB >> 21880986

CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation.

Harry Z Qui1, Adam T Hagymasi, Suman Bandyopadhyay, Marie-Clare St Rose, Raghunath Ramanarasimhaiah, Antoine Ménoret, Robert S Mittler, Scott M Gordon, Steven L Reiner, Anthony T Vella, Adam J Adler.   

Abstract

Cytotoxic CD4 Th1 cells are emerging as a therapeutically useful T cell lineage that can effectively target tumors, but until now the pathways that govern their differentiation have been poorly understood. We demonstrate that CD134 (OX40) costimulation programs naive self- and virus-reactive CD4 T cells to undergo in vivo differentiation into cytotoxic Th1 effectors. CD137 (4-1BB) costimulation maximized clonal expansion, and IL-2 was necessary for cytotoxic Th1 differentiation. Importantly, the T-box transcription factor Eomesodermin was critical for inducing the cytotoxic marker granzyme B. CD134 plus CD137 dual costimulation also imprinted a cytotoxic phenotype on bystanding CD4 T cells. Thus, to our knowledge, the current study identifies for the first time a specific costimulatory pathway and an intracellular mechanism relying on Eomesodermin that induces both Ag-specific and bystander cytotoxic CD4 Th1 cells. This mechanism might be therapeutically useful because CD134 plus CD137 dual costimulation induced CD4 T cell-dependent tumoricidal function in a mouse melanoma model.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21880986      PMCID: PMC3178659          DOI: 10.4049/jimmunol.1101244

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  72 in total

1.  Newly activated T cells promote maturation of bystander dendritic cells but not IL-12 production.

Authors:  Roman Spörri; Caetano Reis e Sousa
Journal:  J Immunol       Date:  2003-12-15       Impact factor: 5.422

Review 2.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

3.  OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis.

Authors:  Matthew Karulf; Ann Kelly; Andrew D Weinberg; Jeffrey A Gold
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

Review 4.  Control of immunity by the TNFR-related molecule OX40 (CD134).

Authors:  Michael Croft
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

5.  Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.

Authors:  Ying Xie; Akgül Akpinarli; Charles Maris; Edward L Hipkiss; Malcolm Lane; Eun-Kyung M Kwon; Pawel Muranski; Nicholas P Restifo; Paul Andrew Antony
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

6.  Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Authors:  Sergio A Quezada; Tyler R Simpson; Karl S Peggs; Taha Merghoub; Jelena Vider; Xiaozhou Fan; Ronald Blasberg; Hideo Yagita; Pawel Muranski; Paul A Antony; Nicholas P Restifo; James P Allison
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

7.  Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells.

Authors:  Matthew E Pipkin; Jilian A Sacks; Fernando Cruz-Guilloty; Mathias G Lichtenheld; Michael J Bevan; Anjana Rao
Journal:  Immunity       Date:  2010-01-21       Impact factor: 31.745

8.  Tracking epitope-specific T cells.

Authors:  James J Moon; H Hamlet Chu; Jason Hataye; Antonio J Pagán; Marion Pepper; James B McLachlan; Traci Zell; Marc K Jenkins
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

9.  IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells.

Authors:  Deborah M Brown; Cris Kamperschroer; Allison M Dilzer; Deborah M Roberts; Susan L Swain
Journal:  Cell Immunol       Date:  2009-03-31       Impact factor: 4.868

10.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

View more
  75 in total

Review 1.  Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.

Authors:  Richard Wu; Marie-Andrée Forget; Jessica Chacon; Chantale Bernatchez; Cara Haymaker; Jie Qing Chen; Patrick Hwu; Laszlo G Radvanyi
Journal:  Cancer J       Date:  2012 Mar-Apr       Impact factor: 3.360

2.  Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.

Authors:  Il-Kyu Choi; Zhe Wang; Qiang Ke; Min Hong; Yu Qian; Xiujuan Zhao; Yuting Liu; Hye-Jung Kim; Jerome Ritz; Harvey Cantor; Klaus Rajewsky; Kai W Wucherpfennig; Baochun Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

3.  Cytokine-dependent induction of CD4+ T cells with cytotoxic potential during influenza virus infection.

Authors:  Laiqing Hua; Shuyu Yao; Duy Pham; Li Jiang; Jeffrey Wright; Deepali Sawant; Alexander L Dent; Thomas J Braciale; Mark H Kaplan; Jie Sun
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

4.  Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.

Authors:  Todd Bartkowiak; Ashvin R Jaiswal; Casey R Ager; Renee Chin; Chao-Hsien Chen; Pratha Budhani; Midan Ai; Matthew J Reilley; Manu M Sebastian; David S Hong; Michael A Curran
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

5.  An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.

Authors:  Payal Mittal; Rebecca Abblett; Joseph M Ryan; Adam T Hagymasi; Archibald Agyekum-Yamoah; Julia Svedova; Steven L Reiner; Marie-Clare St Rose; Matthew P Hanley; Anthony T Vella; Adam J Adler
Journal:  J Immunol       Date:  2018-01-05       Impact factor: 5.422

6.  Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.

Authors:  Bettina Weigelin; Elixabet Bolaños; Alvaro Teijeira; Ivan Martinez-Forero; Sara Labiano; Arantza Azpilikueta; Aizea Morales-Kastresana; José I Quetglas; Esther Wagena; Alfonso Rodríguez Sánchez-Paulete; Lieping Chen; Peter Friedl; Ignacio Melero
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-01       Impact factor: 11.205

7.  Cooperativity of HIV-Specific Cytolytic CD4 T Cells and CD8 T Cells in Control of HIV Viremia.

Authors:  Susan Johnson; Michael Eller; Jeffrey E Teigler; Sebastien M Maloveste; Bruce T Schultz; Damien Z Soghoian; Richard Lu; Alexander F Oster; Agnès-Laurence Chenine; Galit Alter; Ulf Dittmer; Mary Marovich; Merlin L Robb; Nelson L Michael; Diane Bolton; Hendrik Streeck
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

8.  Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients.

Authors:  Laszlo G Radvanyi; Chantale Bernatchez; Minying Zhang; Patricia S Fox; Priscilla Miller; Jessica Chacon; Richard Wu; Gregory Lizee; Sandy Mahoney; Gladys Alvarado; Michelle Glass; Valen E Johnson; John D McMannis; Elizabeth Shpall; Victor Prieto; Nicholas Papadopoulos; Kevin Kim; Jade Homsi; Agop Bedikian; Wen-Jen Hwu; Sapna Patel; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Michael A Davies; Rahmatu Mansaray; Orenthial J Fulbright; Christopher Toth; Renjith Ramachandran; Seth Wardell; Audrey Gonzalez; Patrick Hwu
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

9.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

10.  CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells.

Authors:  Nora Manzke; Ilseyar Akhmetzyanova; Kim J Hasenkrug; Mirko Trilling; Gennadiy Zelinskyy; Ulf Dittmer
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.